5月20日,和誉医药(02256.HK)宣布其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼(ABSK021)被中国国家药品监督管理局药品审评中心(CDE)纳入优先审评,用于需要系统性治疗腱鞘巨细胞瘤(TGCT)的患者。2023年12月,和誉医药与默克公司就匹米替尼的商业化权利达成协议,默克公司将负责匹米替尼在全球的商业化。优先审评制度将大幅缩短匹米替尼的上市审批流程,更快地将药品带给有需要的...
Source Link5月20日,和誉医药(02256.HK)宣布其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼(ABSK021)被中国国家药品监督管理局药品审评中心(CDE)纳入优先审评,用于需要系统性治疗腱鞘巨细胞瘤(TGCT)的患者。2023年12月,和誉医药与默克公司就匹米替尼的商业化权利达成协议,默克公司将负责匹米替尼在全球的商业化。优先审评制度将大幅缩短匹米替尼的上市审批流程,更快地将药品带给有需要的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.